Summary by Moomoo AI
On June 26, 2024, HuaPlat Pharma-B resubmitted the biological product application (BLA) of bartolizumab (HBM9161) to the National Medical Products Administration (NMPA) of China for approval. Bartolizumab is a fully human monoclonal antibody that specifically binds and inhibits neonatal FcRn, and is expected to become a new therapy for various autoimmune diseases in Greater China. The company reminds shareholders and potential investors that it cannot guarantee the successful marketing of this drug and should act prudently. The announcement also includes forward-looking statements, but the company does not guarantee the regular update of these statements and notes that actual results may differ from expectations due to various factors.